Organigram's Q2 2026 Revenue Dips 9% Amid Vape Challenges, Sanity Group Acquisition
Event summary
- Q2 2026 revenue declined 9% YoY to $59.8M, with gross revenue at $93.3M (-9% YoY).
- Adjusted EBITDA plummeted 82% YoY to $0.9M, driven by lower vape and infused pre-roll sales.
- Completed acquisition of Sanity Group, expected to generate €25M in average quarterly revenue.
- Record harvest of 32,000 kg (+56% YoY) and highest THC potency in Moncton facility.
- Updated fiscal 2026 guidance: net revenue now projected to exceed $350M, up from $300M.
The big picture
Organigram's Q2 2026 results reflect broader industry challenges in the Canadian cannabis market, particularly in high-margin product categories like vapes. The Sanity Group acquisition positions the company for international expansion, but execution risks remain. The updated guidance suggests confidence in reversing recent declines, though profitability improvements hinge on operational improvements and successful integration of the new acquisition.
What we're watching
- Operational Recovery
- Whether Organigram can stabilize performance in H2 2026 after addressing vape and pre-roll production challenges.
- International Growth
- The pace at which Sanity Group integration accelerates revenue in key European markets.
- Margin Expansion
- How higher yields and operational efficiencies will impact gross margins in the second half of fiscal 2026.
Related topics